Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。